Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | SCN4A | P35499 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13587136 | 0.78 | CASR (0.33) | CASRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL804959 | 0.78 | SMN1; SMN2 (0.52) | TRPV1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14046224 | 0.78 | ACACB (0.38) | ACACBCASRNPC1SCN4ARAB9A | |
| SCHEMBL798536 | 0.78 | ACACB (0.38) | ACACBCASRNPC1SCN4ARAB9A | |
| SCHEMBL10183352 | 0.77 | RAB9A (0.50) | NPC1SCN4ARAB9ASMN1; SMN2 | |
| SCHEMBL2707208 | 0.74 | NPC1 (0.45) | ACACBCASRTRPV1NPC1SCN4A | |
| SCHEMBL23775746 | 0.74 | ACACB (0.39) | ACACBNPC1SCN4ARAB9ASMN1; SMN2 | |
| SCHEMBL12269123 | 0.72 | TRPV1 (0.42) | TRPV1NPC1SCN4ARAB9ASMN1; SMN2 | |
| SCHEMBL20047441 | 0.71 | GAA (0.41) | ACACBCASRTRPV1NPC1SCN4A | |
| SCHEMBL20047521 | 0.70 | ACACB (0.37) | ACACBTRPV1NPC1SCN4ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11419875-B2 | Compounds and compositions for treating hematological disorders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-08-23 | — | — | US | disclosed |
| US-20220056046-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2022-02-24 | — | — | US | disclosed |
| US-20210290628-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-09-23 | — | — | US | disclosed |
| US-10995100-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-05-04 | — | — | US | disclosed |
| US-20200190112-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2020-06-18 | — | — | US | disclosed |
| US-10640517-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190112-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | ACACB 2741/4885CASR 3833/4885TRPV1 3015/4885 |
| US-20220056046-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | ACACB 2741/4885CASR 3833/4885TRPV1 3015/4885 |
| US-20210290628-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | IRAK4, FLT3, IRAK3 | ACACB 2501/4885CASR 4724/4885TRPV1 4119/4885 |
| US-10640517-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | ACACB 2741/4885CASR 3833/4885TRPV1 3015/4885 |
| US-11419875-B2 | Compounds and compositions for treating hematological disorders | IRAK4, FLT3, IRAK3 | ACACB 2501/4885CASR 4724/4885TRPV1 4119/4885 |
| US-10995100-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | ACACB 2741/4885CASR 3833/4885TRPV1 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.